Company intelligence / Profile preview

Northern Antibiotics Ltd.

- Helsinki/Espoo*, Finland

Ownership: Private
Development stage: Other

Overview

Northern Antibiotics develops novel polymyxin derivative antibiotics designed to combat multidrug-resistant Gram-negative bacteria with reduced nephrotoxicity compared to traditional polymyxins. Their lead compounds have shown promising preclinical efficacy and safety profiles, with some advancing into early clinical trials. The company aims to address urgent medical needs posed by resistant superbugs causing serious hospital infections.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

NAB739

Preclinical

1 more asset in the full pipeline.

Partnerships

Licensed a polymyxin derivative to US-based Spero Therapeutics for further development[5].Seeking commercial partners for late-stage development and human trials[5][7].

Beyond the preview

Go deeper on Northern Antibiotics Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Northern Antibiotics Ltd..